Application of continuous renal replacement therapy in the treatment of neonates with inherited metabolic diseases.
- Author:
Yang HU
1
;
Xiao-Ming PENG
1
;
Zheng-Hui XIAO
Author Information
1. Department of Neonatology, Hunan Children's Hospital, Changsha 410007, China.
- Publication Type:Journal Article
- MeSH:
Acute Kidney Injury;
Child;
Continuous Renal Replacement Therapy;
Female;
Humans;
Hyperammonemia/therapy*;
Infant;
Infant, Newborn;
Length of Stay;
Male;
Metabolic Diseases/therapy*;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(5):488-493
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the efficacy and safety of continuous renal replacement therapy (CRRT) in the treatment of neonates with inherited metabolic diseases and hyperammonemia.
METHODS:A retrospective analysis was performed on the medical records of neonates with inherited metabolic diseases and hyperammonemia who were hospitalized and underwent CRRT in the Department of Neonatology, Hunan Children's Hospital, from September 2016 to March 2020, including general conditions, clinical indices, laboratory markers, and adverse reactions.
RESULTS:A total of 11 neonates were enrolled, with 7 boys (64%) and 4 girls (36%). The neonates had a mean gestational age of (38.9±0.8) weeks, a mean body weight of (3 091±266) g on admission, and an age of (5.7±2.0) days at the time of CRRT. The main clinical manifestations were vomiting (100%), convulsions (100%), and coma (55%), and the main primary disease was urea cycle disorder (55%). The mean duration of CRRT was (44±14) hours, the medium duration of coma before CRRT was 2 hours, and the total duration of coma was 10 hours. The patients had a mean hospital stay of (18±10) days and a survival rate of 73%, and 2 survivors had epilepsy. After treatment, all patients had significant reductions in blood ammonia, lactic acid, and K
CONCLUSIONS:CRRT is safe and effective in the treatment of neonates with inherited metabolic diseases and hyperammonemia.
